Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

RhPDGF-BB:llä tehostetun kollageenitulpan arviointi perianaalisen fistelin paranemiseen

perjantai 6. marraskuuta 2026 päivittänyt: Aimal Khan

Satunnaistettu kontrolloitu koe, jossa arvioidaan ihmisen yhdistelmä-DNA-tekniikalla tehdyn verihiutaleperäisen kasvutekijä B:n (rhPDGF-BB) kollageenitulpan turvallisuutta ja toteutettavuutta monimutkaiseen perianaalifistelien paranemiseen

The average success rate for healing and remission of complex perianal fistulas, idiopathic or Crohn's-related, is approximately 50%. These abnormal connections between the rectum and the outside skin remain a major clinical challenge in need of new treatments aimed at tissue repair. Platelet-derived growth factor drives wound healing and tissue regeneration, and manufactured PDGF is currently used to heal diabetic foot ulcers and regenerate bone in periodontal and orthopedic patients. Manufactured recombinant human PDGF has the potential to improve the success rate for complete healing of complex perianal fistulas, reduce the recurrence rate due to reopening of the fistula tract, and avoid complications associated with routine surgical interventions.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Perianal fistula is a common colorectal condition with an incidence of 9 cases per 100,000. Most perianal fistulas originate from an anal abscess that does not heal properly and are mainly treated with surgical interventions. The type of surgery and healing rates depend on the classification of the fistula as simple or complex and the proportion of the sphincter muscle that is involved. The second most common cause of perianal fistula is due to Crohn's disease (CD), a chronic inflammatory disease with an estimated annual incidence of 3 to 20 cases per 100,000. Approximately 20% of patients with CD will develop a perianal fistula within 10 years of diagnosis. CD-related perianal fistulas are a severe complication of chronic intestinal inflammation and rely on the combination of pharmacological therapies and surgical interventions, but still one-third of CD-related fistulas remain unhealed.

This Phase II clinical trial will evaluate the performance, preliminary safety and efficacy, and feasibility of the rhPDGF-BB-enhanced collagen plug versus routine care on healing complex perianal fistulas that are not eligible for a fistulotomy. This prospective, blinded, single-site study will randomize participants, 2:1 intervention versus control, into two arms comparing the rhPDGF-BB-enhanced collagen plug to routine care procedures and stratify participants by fistula etiology, Crohn's or idiopathic. Routine care includes draining seton removal and natural healing for Crohn's fistulas or COOK Biotech's Biodesign® Anal Fistula Plug implant for idiopathic fistulas. For both non-CD (idiopathic) and CD-related fistulas, a loose seton is an effective first-line treatment to facilitate drainage of the abscess, prevent the recurrence of an abscess, and increase the chance of healing successfully. After seton placement, the therapeutic interventions for idiopathic and CD-related fistulas differ, and the overall healing rates are widely variable in the literature. The outcomes for CD-related perianal fistulas with seton intervention report success rates between 14-81% and idiopathic perianal fistulas with anal fistula plug intervention are highly similar with success rates between 15.8-72.7%.

After recruiting and consenting, participants will be randomized and scheduled for the baseline procedure. Randomization blocks of size 3 (2:1 intervention to control) within each stratum (idiopathic versus CD-related) will be utilized, and the patient will be blinded. The investigator will not be blinded because the control and intervention procedures are different. Following the baseline procedure, participants will return for outcomes assessment by a blinded physician at one month, three months, and six months and complete a weekly participant survey from home. At each study visit, the blinded physician will perform a clinical examination of the external opening to assess for inflammation, drainage, and epithelialization, take clinical photographs, and discuss any adverse events (1-month and 3-month visits only). At the 3-month study visit, the blinded physician will determine if the fistula has completely healed, and this will be documented in the study database. At the 6-month final study visit, the blinded physician will assess for recurrence of the fistula by examination of the external opening, and this will be documented in the study database.

If the fistula is not healing at the 3-month study visit and the participant is in the control arm of the study, they will reach their endpoint as a control and have the option to crossover to the investigational arm and receive the investigational intervention. These participants will first have another draining seton placed in their fistula tract for approximately 3 weeks and be scheduled for the intervention procedure, implantation of the rhPDGF-BB-enhanced collagen plug. This group will restart at visit 2 for the procedure and return for all post-procedural study visits 3-5 at 1-, 3-, and 6-months. Their outcome measures will be tracked and documented, and they will complete the weekly participant surveys, but their results will not be included in the initial analyses of the original randomized participant data. This will be considered extended open-label use of the investigational intervention and will not delay reporting the outcomes from the comparison of healing between the original intervention and control groups at 3 months. Their outcome measures will be analyzed and reported separately.

The natural history and actual case-counts of these two patient populations, idiopathic and CD-related complex perianal fistulas, guided the design of the objectives, outcomes, and sample size that would allow this pilot study to be completed in approximately 15 months. A small, 2:1 randomized, parallel arm design was chosen for the purposes of evaluating preliminary performance, safety, efficacy, and feasibility. The primary objective of this study is to evaluate the technical performance of the rhPDGF-BB-enhanced collagen plug for the treatment of complex perianal fistulas regardless of etiology. This outcome measure is defined as procedural success of the rhPDGF-enhanced collagen plug without any intervention-related serious adverse events. Procedural complications include but are not limited to acute infection, dislodgement or extrusion of the plug, and non-healing of the fistula tract. The secondary objectives that are focused on the potential efficacy of this treatment will include a stratified subgroup analyses for idiopathic and CD-related fistulas due to the differences in natural history and potential differences in outcomes with routine care in these two groups. Further, the stratified, randomized design will promote balance of the etiologies across the trial arms. For this pilot, published data and the investigator's real-world experience with healing in these patients were used to design the objectives and outcomes that will guide a larger more definitive follow-up trial where assessing efficacy may or may not include both etiologies. Given the number of different perianal fistula types, anatomical presentations, and approaches to treatment, the inclusion criteria are specific to fistulas that are a single continuous tract, have had a draining seton placed, and are not amenable to fistulotomy regardless of etiology. The study design, control groups, and inclusion criteria support the endpoint analyses at 1-, 3-, and 6-months post intervention based on historical data for healing, remission, and recurrence of perianal fistulas.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

13

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Tennessee
      • Nashville, Tennessee, Yhdysvallat, 37203
        • Vanderbilt University Medical Center

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

22 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Diagnosis of a single tract perianal fistula not amenable to fistulotomy as determined by the supervising surgeon
  • Fistula must currently have a draining seton in place
  • Aged >21 years old
  • Willing and able to provide informed consent and to comply with study protocol and follow-up
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion Criteria:

  • Medical conditions that would, in the opinion of the investigator or treating provider, compromise the safety of the individual with study participation and/or the ability of the individual to follow study protocol
  • Genito-urinary fistulization, including rectovaginal (i.e., fistulas that transverse the vaginal canal)
  • Presence of an ileal anal pouch
  • Any major surgery of the gastrointestinal tract (including one or more segments of the colon or terminal ileum) within 3 months prior to randomization; presence of stoma is not exclusionary
  • Prior surgical procedure (i.e., Ligation of Intersphincteric Fistula Tract or Endorectal Advancement Flap) for the target fistula or a perianal procedure that resulted in a large soft tissue defect within 6 months prior to screening visit
  • One or more of the following fistula types or anatomic presentations: horseshoe fistulas, fistulas that do not have an opening inside the anal canal or low rectum, blind ending sinus tracts (no external opening), branching fistulas (a previously performed conversion of a branching fistula tract to a single tract is not exclusionary), >1 internal opening, moderate or severe proctitis, severe rectal mucosal fibrosis surrounding the internal opening preventing the securing of the fistula plug disk, any anatomical limitation to successfully securing the fistula plug disk.
  • Known allergic reactions to porcine collagen or yeast-derived products
  • Currently enrolled in a drug or device trial or within 30 days of last investigational drug or device administration at baseline visit where investigational treatment (drug or device) was placed in or near the fistula tract or may potentially interact with study treatment
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
  • Active infection at the application site
  • The presence of malignant neoplasms at the application site
  • Prior radiation therapy at the application site

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kolminkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Ei väliintuloa: Routine care

Participants receive routine care for their fistula.

Kokeellinen: rhPDGF-BB-enhanced collagen plug

Participants receive collagen plug saturated with rhPDGF-BB.

0.3 mg/mL rhPDGF-BB

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Participants Without Treatment-Related Serious Adverse Events (SAEs) at 3 Months
Aikaikkuna: Month 3

Proportion of participants with procedural success as defined by implantation of the device without device-related SAEs.

Month 3

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Participants Who Achieved Fistula Healing at 3 Months
Aikaikkuna: Month 3

Fistula healing is a binary endpoint (healed or not healed) that will be determined by an evaluation from the blinded physician confirming whether there is visible drainage from the external opening.

Month 3
Number of Participants With Fistula Recurrence at 6 Months
Aikaikkuna: Month 6

A participant that was diagnosed with a healed fistula that is diagnosed with recurrence of the fistula by clinical evaluation of the external opening at the 6-month follow-up visit.

Month 6
Change from Baseline in Symptoms at Week 24
Aikaikkuna: From enrollment to week 24

Weekly self-reported participant surveys assessing the prevalence of perianal fistula-related symptoms (including pain, incontinence, and missed days of school or work).

From enrollment to week 24
Change from Baseline in Pain on an 11-Point Scale at Week 24
Aikaikkuna: From enrollment to week 24

Weekly self-reported participant surveys will be assessing average pain intensity through an 11-point scale. Possible scores range from 0 (No Pain) to 10 (Worst Pain).

From enrollment to week 24
Change from Baseline in Incontinence on a 5-Point Scale at week 24
Aikaikkuna: From enrollment to week 24

Weekly self-reported participant surveys measuring incontinence with 5 questions (adapted from Wexner Incontinence Score) using a 5-point ordinal scale from 0 (Never) to 4 (Always (once or more per day)).

From enrollment to week 24
Number of Participants Recruited and Eligible
Aikaikkuna: Monthly up to month 15

Total number of participants that were recruited and eligible for the study.

Monthly up to month 15
Number of Participants Randomized Per Month
Aikaikkuna: Monthly up to month 15

Number of participants that were randomized each month of the study.

Monthly up to month 15
Proportion of Participants Retained at 3 and 6 Months
Aikaikkuna: Month 3 and month 6

Proportion of participants retained in the study at the 3 month and 6 month endpoints.

Month 3 and month 6
Summary of Device-Related Adverse Events (AEs)
Aikaikkuna: Month 3

A quantitative and descriptive summary of all device-related AEs. Relationship to study intervention will be assessed by the clinician who examines and evaluates the participant based on temporal relationship and his/her clinical judgment.

Month 3

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Crossover Outcomes
Aikaikkuna: Month 3

The proportion of crossover participants that are completely healed at 3-months following the investigational procedure.

Month 3

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Alexander T Hawkins, Vanderbilt University Medical Center

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 25. marraskuuta 2024

Ensisijainen valmistuminen (Todellinen)

Perjantai 19. kesäkuuta 2026

Opintojen valmistuminen (Todellinen)

Perjantai 24. heinäkuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 2. lokakuuta 2024

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 7. lokakuuta 2024

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 9. lokakuuta 2024

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 12. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 6. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

PÄÄTTÄMÄTÖN

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa